Search results
Results from the WOW.Com Content Network
Blocking SGLT-2 reduces blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine. [ 43 ] [ 44 ] [ 45 ] Of all the SGLT-2 Inhibitors currently available, empagliflozin has the highest degree of selectivity for SGLT-2 over SGLT-1, SGLT-4, SGLT-5 and SGLT-6.
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).
SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. [2] [3] As of 2014, several medications of this class had been approved or were under development. [4]
An alternative to statins may help reduce deaths from heart disease among people with high levels of LDL, or “bad” cholesterol, new research finds.. When taken as a daily pill, bempedoic acid ...
Includes factors that can increase the risk of heart disease, such as kidney disease, obesity and a marker of poor blood sugar control (hemoglobin A1C). Calculates risk separately for men and women.
Prediabetes, often considered the step before diabetes, is when you have higher than usual blood glucose (blood sugar) levels. Your levels aren’t high enough to be classified as type 2 diabetes.
Ozempic has become a blockbuster drug thanks to its ability to help people lose weight, but Mounjaro, another Type 2 diabetes treatment, appears to be far more effective for weight loss, a new ...
In March 2012, the U.S. Food and Drug Administration (FDA) updated its guidance for statin users to address reports of memory loss, liver damage, increased blood sugar, development of type 2 diabetes, and muscle injury. [26] The new guidance indicates: FDA has found that liver injury associated with statin use is rare but can occur. [citation ...